B7-2
| T-lymphocyte activation antigen CD86 | ||
|---|---|---|
|
||
| soluble variant of B7-2 | ||
| other names |
Activation B7-2 antigen, B70, BU63, CTLA-4 counter-receptor B7.2, FUN-1, CD86 |
|
| Properties of human protein | ||
| Mass / length primary structure | 329 amino acids , 37,682 Da | |
| Identifier | ||
| External IDs | ||
| Orthologue (human) | ||
| Entrez | 942 | |
| Ensemble | ENSG00000114013 | |
| UniProt | P42081 | |
| Refseq (mRNA) | NM_001206924.1 | |
| Refseq (protein) | NP_001193853.1 | |
| PubMed search |
942
|
|
B7-2 , often referred to as CD86 in the literature , is a surface protein from the immunoglobulin superfamily . As a costimulator , it is involved in the activation of T cells in the course of the immune response .
properties
B7-2 is expressed by activated B cells and monocytes and forms homodimers . Activation via a co-stimulator provides the necessary second activation signal for T cells. B7-2 binds to CD28 (T cell activating) or CTLA-4 (T cell inactivating). The isoform 2 of B7-2 inhibits the binding of the isoform 1 to each other, thereby inhibiting the activation. B7-2 is glycosylated and has a similar function to B7-1 .
B7-2 is the cellular receptor of the adenoviruses of group B.
Web links
Individual evidence
- ↑ S. Bhatia, M. Edidin, SC Almo, SG Nathenson: B7-1 and B7-2: similar costimulatory ligands with different biochemical, oligomeric and signaling properties. In: Immunology letters. Volume 104, Number 1-2, April 2006, pp. 70-75, doi : 10.1016 / j.imlet.2005.11.019 , PMID 16413062 .
- ^ Charles Janeway: The production of armed effector T cells. In: Immunobiology (2001). February 3, 2017, accessed May 17, 2017 .